Funding

AstraNu Raises $3.5M in Seed Funding led by Celesta Capital

Nov 18, 2026 | By Devin Jacobs

AstraNu Raises $3.5M in Seed Funding led by Celesta Capital

SUMMARY

  • AstraNu raised $3.5 million in Seed funding.
  • It will use the funds to develop its imaging technology.
  • AstraNu develops imaging technology for medical devices.

AstraNu, a Murray Hill, NJ-based provider of a chip-scale optical coherence tomography (OCT) imaging solution for the medical device industry, has raised $3.5 million in a Seed funding round.

The round was led by Celesta Capital with participation from the New Jersey Innovation Evergreen Fund (NJIEF), a program of the New Jersey Economic Development Authority (NJEDA).

The company will use the funding to expand its photonics development team, validate its imaging technology and prepare for volume manufacturing.

What is AstraNu?

AstraNu develops chip-scale optical coherence tomography (OCT) imaging technology for medical device manufacturers. Its imaging engine is designed to deliver high-performance scans in a smaller and more affordable package than conventional swept-source OCT systems.

Read More:Mulga Raises $1.77M in Pre-Seed Funding for Spinifex

OCT is an imaging technology used to capture detailed views of tissues inside the body. Swept-source OCT (SS-OCT) can provide faster and deeper imaging than older spectral domain OCT (SD-OCT) systems, but its size and cost have limited wider adoption.

AstraNu's technology aims to address these challenges. Developed at Nokia Bell Labs, its imaging engine delivers swept-source performance at price points associated with spectral-domain OCT. The module is more than 10 times smaller than conventional swept-source systems.

The company supplies its technology to established medical device, imaging and optics businesses that want to integrate advanced OCT imaging into their products.

About AstraNu

How Much Funding Has AstraNu Raised?

AstraNu has raised $3.5 million in its Seed funding round. The company has not disclosed its total funding raised or details of other previous financing rounds.

Who Invested in AstraNu’s Seed Round?

The $3.5 million Seed round was led by Celesta Capital.

The New Jersey Innovation Evergreen Fund (NJIEF), a programme of the New Jersey Economic Development Authority, also participated.

Celesta Capital had previously backed AstraNu as part of its collaboration with Nokia Bell Labs to commercialise technologies developed by the research organisation.

Why the Funding Matters

AstraNu plans to use the new capital to expand its photonics development team and validate the performance of its imaging engine.

The funding will also support preparations for volume manufacturing as the company moves towards commercial deployment with application partners.

These steps will help AstraNu demonstrate its technology to medical device manufacturers and prepare it for integration into their products.

AstraNu funding

Who founded AstraNu?

AstraNu was founded in 2025 by Michael Eggleston and Bibek Samanta. The company spun out of Nokia Bell Labs in May 2025 and is headquartered in Murray Hill, New Jersey.

It was the first venture launched through the collaboration between Nokia Bell Labs and Celesta Capital to commercialise Bell Labs technologies.

"AstraNu is an outstanding example of where we invest: foundational technology from one of the world's leading research labs, with the potential to change what is possible in a large and established market," said Matthew Marsh, Managing Partner and CFO of Celesta Capital. "By delivering a new cost and performance package, AstraNu is opening this imaging technology to entirely new applications and markets.

Market and Business Growth

Since its spinout in 2025, AstraNu has achieved swept-source OCT performance at chip scale and is preparing to demonstrate and validate the technology with application partners.

The company is initially targeting the ophthalmology market, where OCT is widely used for medical imaging. It is also exploring opportunities in ENT, urology and oncology.

Its technology is designed for medical device manufacturers and imaging companies that want to add high-performance OCT capabilities without using the larger and more expensive conventional swept-source systems.

What Happens Next?

AstraNu plans to expand its development team, complete performance validation and prepare its imaging engine for volume manufacturing.

The company will also work with application partners and medical device developers to demonstrate the technology, and explore its use across different clinical fields.

Read More:Archive360 Appoints Manouj Tahiliani as Chief Executive Officer

Recommended Stories for You